(fra kommisjonsbeslutningen)

(1) IPBC was approved as an active substance for use in biocidal products of product-type 13 by Commission Implementing Regulation (EU) 2015/1728 (2) subject to the conditions set out in the Annex to that Regulation.

(2) The approval of IPBC for use in biocidal products of product-type 13 (‘the approval’) is to expire on 30 November 2026. On 28 May 2025, an application was submitted in accordance with Article 13(1) of Regulation (EU) No 528/2012 for the renewal of the approval of IPBC for use in biocidal products of product-type 13 (‘the application’).

(3) On 10 March 2026, the evaluating competent authority of Denmark informed the Commission that it had decided, pursuant to Article 14(1) of Regulation (EU) No 528/2012, that a full evaluation of the application was necessary. Pursuant to Article 8(1) of that Regulation, the evaluating competent authority is to perform a full evaluation of the application within 365 days of its validation.

(4) The evaluating competent authority may, as appropriate, require the applicant to provide sufficient data to carry out the evaluation, in accordance with Article 8(2) of Regulation (EU) No 528/2012. In that event, the 365-day period is suspended for a period that may not exceed 180 days in total unless a longer suspension is justified by the nature of the data requested or by exceptional circumstances.

(5) Within 270 days of receipt of a recommendation from the evaluating competent authority, the European Chemicals Agency is to prepare and submit to the Commission an opinion on renewal of the approval of the active substance in accordance with Article 14(3) of Regulation (EU) No 528/2012.

(6) On 10 March 2026, the evaluating competent authority informed the Commission that the application includes new studies submitted by the applicant compared to the approval’s initial dossier and that the evaluation is delayed for reasons beyond the control of the applicant. The Commission deduced from the information provided by the evaluating competent authority that it is unlikely that the evaluating competent authority will submit a recommendation to the European Chemicals Agency before the end of 2027.

(7) Consequently, for reasons beyond the control of the applicant, the approval is likely to expire before a decision has been taken on its renewal. It is therefore appropriate to postpone the expiry date of the approval for a period of time sufficient to enable the examination of the application. Taking into account the time-limits for evaluation by the evaluating competent authority, for preparation and submission by the European Chemicals Agency of its opinion and the time needed for the Commission to decide whether to renew the approval of IPBC for use in biocidal products of product-type 13, the expiry date should be postponed to 31 May 2029.

(8) After the postponement of the expiry date of the approval, IPBC remains approved for use in biocidal products of product-type 13 subject to the conditions set out in the Annex to Implementing Regulation (EU) 2015/1728,